SMARTag™ Antibody Drug Conjugate Technology | Why Catalent?
Summary: The SMARTag™ Antibody Drug Conjugate technology platform offers ADC developers a new toolkit to develop optimized bioconjugates. Developed by Redwood Bioscience, the technology overcomes the limitations associated with conventional protein chemistries that produce heterogeneous products with variable conjugate potency, toxicity and stability. The SMARTag technology enables site-specific, controlled drug-protein conjugation and uses only naturally occurring modifications to proteins requiring minimal cell-line engineering. Developers can now have control over conjugate configuration, generating ADCs with optimal efficacy, safety and stability. The systems also uses proprietary linker chemistry that prevents systemic drug loss and increases targeted potency.